Melanoma Research Alliance Progress Report 2013–2014 Contents

About Us 4

Science 7

Policy 16

Partnerships & Support 18

Events 21

Outreach & Communications 24

Supporters & Financials 28

1 Letter From the Chair & President

This year has seen game-changing progress on treatment of melanoma, including the first anti- behalf of melanoma patients. New treatments are PD-1 drugs, dramatically improving the outlook for saving lives and providing real hope that we are patients. Melanoma research has energized the closer than ever to our goal of eliminating suffering entire field of oncology and charted a new course and death from melanoma. in cancer treatment for a variety of tumor types.

At the Melanoma Research Alliance (MRA), we This report summarizes our many exciting are committed to funding cutting-edge research accomplishments over the past 12 months and to speed the delivery of cures for all melanoma puts in perspective our strategy to capitalize on patients and everyone at risk for this deadly the progress made. We know that our work is not disease. yet finished, as existing treatments still benefit too few melanoma patients, and there is much left to In 2014, MRA awarded a historic $11 million do in identifying better ways to prevent, detect and in research funding to 34 investigators at 19 treat this disease. Through partnerships with all academic institutions, increasing MRA’s cumulative stakeholders and a firm commitment to fund the total funding since we began in 2007 to more than most impactful scientific research, we are building $60 million. MRA’s investment has catalyzed an on the momentum in the field and leading the additional $66 million in leveraged funding from way toward revolutionary approaches in cancer other sources, which brings the total applied to treatment. We are grateful to the many individuals, melanoma research as a result of MRA to $126 organizations, government leaders, and companies million. whose support has enabled us to have enormous impact. Together, with your support, we will defeat The field of melanoma research has never been melanoma. more exciting, thanks to recent success with the dual approaches of targeted therapies and immunotherapy treatment. MRA’s leadership in

funding transformative research has accelerated Debra Black Wendy Selig the development of these novel approaches, Chair and Co-Founder President and CEO funding critical studies that evaluate combinations, mechanisms of action and resistance, and biomarkers. Since MRA’s launch in 2007, seven new therapies have come onto the market for the

#1 Grant Giving Disease Foundation 3 About Us Hallmarks of the Program Key aspects of the MRA research portfolio include: “MRA’s sophisticated model has improved outlooks for patients on multiple fronts. It is the most effective Encouraging Collaborative Team Science organization driving melanoma research in the world—and Team Science Awards fund multidisciplinary research groups and a textbook example of what a disease-specific organization 1 account for 70 percent of research funding to date, followed by a variety should look like.” of individual awards.

– Michael Milken, MRA Board Member and Milken Institute Chairman Funding the Best and Growing the Field As of July 2014, MRA has funded 209 Principal Investigators (PIs) at 92 The Melanoma Research Alliance (MRA) is a unique foundation launched in 2 institutions in 14 countries, and more than half of the PIs awarded per 2007 by Debra and Leon Black with a clear mission—to end suffering and year are new investigators to MRA. death caused by melanoma, the deadliest form of skin cancer. By collaborat- ing with all stakeholders, MRA directs critical resources to accelerate powerful research, advance cures for all patients and prevent more melanomas. Due to the generosity of MRA’s founders, 100% of all donations support MRA’s scien- Supporting Young Investigators tific programs. The Young Investigator Awards program focuses on attracting and 3 supporting the next generation of melanoma research leaders and has The incidence of skin cancer is rising. In the United States, melanoma rates grown to 56 MRA young investigators to date. have tripled over the last three decades. Defeating melanoma has become a public health imperative. Today, we are facing a skin cancer epidemic, but there is cause for hope. MRA is working to change the landscape for patients Investing in Accelerating New Treatments with melanoma and everyone who is at risk. But we need global support and collaboration to achieve this mission. Approximately 88 percent of research funding is directed at melanoma 4 treatment science, with 18 clinical trials and 46 treatment approaches supported, including every melanoma treatment approved since 2011. Join us, and help us win the fight Notably, owing to MRA’s support of $26M in immunotherapy research, against melanoma. MRA has advanced the field’s knowledge of immune checkpoint inhibitors targeting CTLA4 and PD-1 that is being rapidly translated beyond melanoma to many other cancer types.

4 5 Science

Update on Science and Treatment Landscape Historically, options for patients with metastatic melanoma have been severely limited, but MRA’s research investments are improving the understanding and application of therapeutic agents and approaches. Many of these advances also spotlight melanoma as a case study for new treatment modalities for all of oncology. Seven new melanoma therapies have been approved since MRA’s launch in 2007, including the first immune checkpoint blocking drug (ipilimumab), the first molecularly targeted therapy (vemurafenib) and its companion diagnostic, as well as dabrafenib and trametinib as single agents in 2013 and in 2014 as the first combination therapy for melanoma. In 2014, the “next genera- tion” immune checkpoint blocking agents targeting PD-1 have come onto the market and are showing great promise in many other cancers as well.

MRA Research Funding Per Year:

$ 11.4M “When we started this, the best $10.6M

$10M treatment we had was chemotherapy. $8.6M $8.4M In these seven years, everything’s $7.6 M $7.9 M changed. We now have active $5.9M immunotherapy for the first time that $5M actually improves survival. And all of a sudden, chemotherapy is second-, third- or fourth-line treatment for $0 melanoma.” 2008 2009 2010 2011 2012 2013 2014 – Paul Chapman, M.D., Chair of MRA’s Medical Advisory Panel

6 About Us 7 Funded to Date: Funding by Award Type & Scientific Area MRA provides support for cutting-edge translational research programs any- Team Science Awards fulfill one of MRA’s primary goals: to foster a where in the world that have the potential to transform the field. The majority collaborative research process. Multidisciplinary teams consist of Principal of MRA’s investment is focused on treatment science, including studies to 47 Investigators with complementary expertise from the same institution, improve current therapies by identifying new biomarkers and combining treat- Teams inter-institutional, and/or international. Team science projects promote ments aimed at countering drug resistance. MRA is also focused on discover- transformational melanoma research advances with the potential for rapid ing new and more effective drug targets. The importance of these projects is to clinical translation. understand how to achieve superior therapeutic results with the agents used either singly or in combination and to determine which patients will benefit from therapies. MRA also supports the development of prevention strategies and the identification of new biomarkers for prognostics and staging. Established Investigator Awards support investigators with an 32 established record of scientific productivity and accomplishment and who Established Investigators are past the initial four years of their first academic faculty appointment.

Commitments in Research

Young Investigator Programs aim to attract early career scientists with novel ideas into melanoma research, thereby recruiting and supporting the 56 next generation of melanoma researcher leaders. Young Investigators are Young Investigators scientists within four years of their first academic faculty appointment. A mentorship commitment from a senior investigator is required.

Pilot Awards fund potentially transformative ideas that do not have extensive preliminary data but articulate a clear hypothesis and translational 12 goals. Resources for such “high-risk, high-reward” projects are important Pilot & Development to establish proof-of-concept, which may then leverage additional funding Projects through more traditional avenues. Development awards are a subtype in which one year of funding is provided. $3.8 M $3.6 M $53 M Diagnosis/ Prevention Treatment Staging

Academic-Industry Partnership Awards are designed to facilitate 11 interactions between the academic and industrial research sectors, and Academic-Industry are co-supported by MRA and an industrial partner whose involvement is Partnerships essential to the project.

8 Science 9 Improving the Understanding & Treatment MRA Progress Metrics of Melanoma Brain Metastases In just seven years of active research, the productivity of MRA-funded investigators has been high, as Brain metastases are one of the most difficult-to-treat complications of mel- measured by tangible outcomes and promising early results that have advanced the understanding of anoma. To develop effective therapies, more information is needed about the melanoma initiation and progression and the development of new therapies for patients: how melanoma is able to spread and grow in the brain. MRA is supporting programs totaling $2.1 million in research funding to advance this area of critical unmet need. Michael Davies, M.D., Ph.D., at the University of Texas MD Anderson Cancer Center, with the support of an MRA Young Investi- gator Award, found that melanomas that grow in the brain exhibit unique molecular features compared to metastases at other sites in the body, even $ in the same patient. Dr. Davies’ subsequent Team Science Award is sup- 66M porting a novel study to investigate a BRAF inhibitor alone or in combination clinical trials to raised with a MEK inhibitor in patients to understand how well the treatment is in leveraged funding test new melanoma from government, industry and able to penetrate brain tumors and to determine possible mechanisms that treatments other sources the tumors might use to develop resistance against this therapy. Findings from Dr. Davies’ studies, and other MRA-funded research in this area, have informed and accelerated clinical trials for patients.

Total Funding by Award Type, 2008-2014 21 125 patent applications papers published in high- filed for new research and impact journals describing treatment technology results of MRA research

Team Science: $41.5M

Established Investigator: $7.6M

Young Investigator: $7.2M

M 170 Pilot / Development: $1.0 600 initiated new collaborations investigator presentations and strengthened between Partnership: $3.1M delivered at conferences around academia, government and the world industry

10 Science 11 Leveraged Funding Global Presence MRA Investment $60.5 M MRA seeks out opportunities to connect researchers across multiple continents, supporting promising projects around the world. To date, MRA research awards have supported 92 institutions in 14 countries, highlighting Leveraged Funding $66.0 M the commitment to the global fight against melanoma.

Advancing Immunotherapy in Melanoma and Other Cancers MRA-funded research has been central to advancing a particularly promising class of molecules that boosts the immune system against melanoma. These agents, so- called immune checkpoint inhibi- tors, include the FDA-approved anti-CTLA4 agent ipilimumab and the anti-PD-1 agent pembrolizum- ab. The data that MRA-funded scientists have generated in United States, In 2014, MRA joined with the Saban Family Foundation to provide funding understanding anti-PD-1 antibod- Australia, for three interdisciplinary teams, each led by a Principal Investigator at an ies is now being used by cancer researchers working on colon, breast, institution in Israel. One of the Saban Family Foundation-MRA Team Science brain, pancreatic, kidney, prostate, bladder, leukemia, lymphoma and lung Belgium, Canada, Awards includes funding for investigators at the Hebrew University of cancer immunotherapy. With $13 million in support focusing on immune England, France, Jerusalem, the University of Colorado and the University of North Carolina to checkpoint inhibitors from MRA since 2008, researchers are focused on study new melanoma therapeutic targets. further understanding the mechanisms underlying therapy, identifying Germany, Israel, treatment-related biomarkers, and developing combinatorial therapy ap- Netherlands, New International collaborations such as these are needed to spark new ideas and proaches. An MRA Team Science Academic-Industry Partnership Award accelerate time frames to improve the treatment of melanoma. These Team being led by Jedd Wolchok, M.D., Ph.D., at Memorial Sloan Kettering Zealand, Norway, Science Awards represent the first regionally targeted funding opportunity Cancer Center is supporting research in this area, defining the mechanisms Spain, Sweden, for MRA and illustrate why collaboration and global reach are essential in the for the potential synergistic effect of the anti-PD-1 agent nivolumab with fight against melanoma. ipilimumab that will help determine which patients will benefit most from Switzerland this combination strategy.

12 Science 13 Annual Scientific Retreat In February 2014, MRA convened its Sixth An- panel featuring Milken Institute Chairman nual Scientific Retreat in Washington, DC. The Michael Milken and former U.S. Senator retreat brought together more than 300 leaders Connie Mack, both MRA Board Members, and from academia, industry, nonprofits, and gov- journalist and author Cokie Roberts. This year, ernment to share early findings, identify future MRA also convened a meeting of skin cancer directions, discuss ideas and look for synergies and melanoma foundations, providing the and partnerships. MRA was joined by a number coalition with a forum for sharing best practices of individuals from around the world represent- and a platform to co-fund MRA-vetted research. “I was extremely impressed with the high level of the ing 77 institutions, 29 companies, more than scientific presentations. It was encouraging to see a dozen collaborating foundations and many MRA published Converging on a Cure, summa- engaged patients. rizing the meeting highlights, emphasizing the the active participation of academic, industry, and importance of cross-sector and inter-disciplinary Retreat attendees heard results from the world’s collaborations, catalyzed by MRA’s model of government groups—an ideal process for accelerating leading melanoma researchers, as well as engaging the leaders in the field. the pace of development and registration of melanoma testimonials from melanoma patients directly impacted by this work. MRA hosted a solutions- treatment options.” oriented session with industry and FDA to promote new models for advancing earlier stage – Tom Hall, Senior Principal Scientist, Pfizer therapies and presented a lunchtime discussion

14 Science 15 Policy

MRA is uniquely positioned to leverage its scientific credibility and reach in the public policy arena to advance better prevention, detection and treatment approaches. MRA has led and contributed to a number of efforts aimed at policy-makers, “MRA provides unique scientific leadership and policy expertise. urging them to help in the fight against deadly skin cancer. We relied on MRA as a leading member of our successful coalition effort to enact legislation that will bring innovative new sunscreen products to Americans and help prevent melanoma.”

– Michael J. Werner, Partner, Holland & Knight, LLP Regulatory Engagement Surgeon General’s Call to Action PASS Coalition Department of Defense and NIH By working collaboratively with the FDA and MRA has been central to engaging public health industry, MRA addresses key regulatory leaders in a melanoma prevention strategy. These MRA is an active member of the Public Access Funding for Research roadblocks that challenge the development efforts spurred the development and recent pub- to SunScreens (PASS) Coalition whose goal is MRA is a leading member of several influential of new cancer therapies and devices, in- lication of a Surgeon General’s Call to Action on to work collaboratively with the FDA, the White coalitions, such as United for Medical Research cluding issues relating to expanded access Preventing Skin Cancer, released in July 2014. House, Congress, health providers, consumer (UMR) and the National Coalition for Cancer through clinical trials and compassionate organizations and sunscreen manufacturers to Research (NCCR), the Alliance for a Stronger use. MRA leadership has provided guidance Tanning Bed Bans for Minors / establish a transparent process for pre-market FDA, and Research!America, whose ongoing approval of sunscreen ingredients. The to the FDA in its implementation of the new Reclassification efforts advocate for sustained funding increases “Breakthrough Therapies” designation, aimed Coalition’s efforts led to the passage of the at the FDA, NIH, and National Cancer Institute to accelerate and streamline the process for MRA strongly supports efforts among federal Sunscreen Innovation Act, bipartisan legislation (NCI). Working in collaboration with other drug approvals. Additionally, MRA continues and state legislatures to reduce the use of indoor that alleviates the 12-year backlog of ingredients organizations, MRA has been instrumental in to engage senior FDA leadership in strategic tanning devices. Today, 11 states across the U.S. to ensure the public has access to innovative urging Congress to provide additional research discussions to speed patients’ access to new have adopted bans that prohibit minors under 18 sunscreen products. funding for melanoma through the Department treatment options. years of age from using indoor tanning beds. At the of Defense (DoD) Peer Reviewed Cancer federal level, MRA was an active proponent of the Research Program. Recognition by the federal reclassification of tanning beds from Class 1 (low risk) government of the direct link between the to Class 2 (moderate risk) devices. incidence of melanoma among our nation’s military and prolonged exposure to UV radiation during active service is an important step in fighting melanoma.

16 17 Partnerships Collaborative Funding Testimonial: & Support Sonja Plesset, Ph.D.

Sonja Plesset is Vice President for Advancement at Whitehead Institute for “MRA Academic-Industry Partnerships accelerate progress Biomedical Research, a leading non-profit research institution dedicated by co-funding research and facilitating academic and to improving human health through biomedical research. In 2013, MRA launched its first partnership with Whitehead, supporting Whitehead Member industry research collaboration to catalyze the next wave Dr. Piyush Gupta through a collaboratively funded Young Investigator Award. of innovation in melanoma.” When I first met with Dr. Piyush Gupta to discuss his melanoma research, I – Jeff Legos, Ph.D., Vice President, Medicines Development was shocked to learn that while there are targeted drugs for BRAF-mutated Leader, GlaxoSmithKline Oncology R&D melanoma, resistance develops in 100% of patients. Moreover, nearly half of patients have a BRAF mutation.

Our Approach During my first call with MRA, I learned the organization was interested in translational work as well as high-risk, high-reward research supported by Innovative partnerships remain central to MRA’s activities—from its team re- strong preliminary data. Piyush’s research seemed an excellent fit—and a search funding approach to its allies who help the organization realize its vision. particularly good match for MRA’s Young Investigator Award. Since its inception, MRA has made great strides with its industry, corporate and non-profit allies program, establishing and growing collaborations with We invited MRA to visit Whitehead Institute, and Piyush explained that more than 100 organizations to fund research, increase sun safety awareness despite improved patient outcomes, all patients eventually develop resis- and support policy initiatives. tance to BRAF-targeting treatments, and six to eight months after treatment, resistant cells emerge and cause relapse. He submitted a strong research Collaborative Funding Model proposal that outlined his strategy to revise these therapies, arguing that if In 2012, MRA began pioneering a novel collaborative funding program with he could identify the molecular mechanisms by which cancer cells tolerate academic institutions around the world to pursue matched support for scientif- BRAF inhibitors then, perhaps, he could use inhibitors of these found path- ically meritorious research that falls outside MRA’s full funding pay line. Through ways in combination with approved BRAF inhibitors to prevent recurrence. this vehicle, MRA can stretch its resources to support a greater number of research projects, engage new donors in MRA’s work, recruit melanoma We were delighted when the news arrived that MRA wished to support his researchers and encourage the growth of institutional melanoma programs. research through the organization’s collaborative funding vehicle, and I am MRA introduced the model in 2013 through a partnership with Duke University confident that this is the start of a very productive partnership. At the end of to fund a Young Investigator Award. Since then, MRA has greatly expanded the day, our goals are completely aligned—we want to ensure Piyush has the pilot program to involve eight other academic institutions. As a result of the funding he needs to complete his ambitious project, which could yield a these efforts, MRA has raised approximately $2 million for research projects novel combination therapy and improve outcomes in BRAF-mutated mela- that would have otherwise not received support. MRA strives to continue to noma patients. shepherd this program around the world, demonstrate the capacity to co-fund through this novel mechanism and improve and adjust it year after year.

18 19 Events

“Over the past four years, Sports Authority has partnered During the past year, MRA has with MRA to educate the public on ways to reduce their continued to expand its funding risk of melanoma while raising funds to support its treat- scope by hosting gatherings ment and cause. Our annual point-of-sale donation cam- across the country to engage paign, coupled with MRA’s innovative program to spread new supporters and elevate the awareness, encourages employees and shoppers to give importance of melanoma among back to melanoma research.” varied audiences. – Mike Foss, Chief Executive Officer, Sports Authority

20 Partnerships & Support 21 Leveraged Finance Fights Sotheby’s Melanoma

MRA’s third benefit dinner drew a devoted group of philanthropists, scientists In recognition of Melanoma Awareness Month, individuals from Wall Street and corporate allies to Sotheby’s New York City headquarters and raised a gathered to network and raise funds and awareness for melanoma at the third record-breaking $6 million. The evening featured addresses by MRA’s leader- annual Leveraged Finance Fights Melanoma (LFFM) event at Rockefeller ship and 2013 Young Investigator Tara Gangadhar, M.D. The live auction, led Center. MRA Board Member Michael Milken spoke at the 900-person event by Jamie Niven, Sotheby’s chairman of North and South America, was the and the evening raised $1.4 million, surpassing last year’s totals for both pinnacle of the evening, with attendees pledging to support 11 new Young attendees and funds raised. Investigator Awards.

22 Events 23 Outreach & Communications L’Oréal Paris Partnership—Thunderclap L’Oréal Paris launched the “It’s THAT Worth It” Thunderclap campaign in the spring as part of an ongoing collaboration with MRA that is funding the MRA-L’Oréal Paris Team Science Award led by Dr. Meenhard Herlyn of Wistar Institute. The campaign culminated on May 20 when over 2,700 social media MRA continues to gain visibility, funding and accounts jointly broadcast a synchronized message of melanoma awareness and support for MRA to a combined audience of over 7 million people. For support through multifaceted approaches each supporter who signed up for the Thunderclap, L’Oréal Paris donated $1 to MRA’s research program. The company also produced a collection of digital with the press and its corporate and and print PSAs that highlighted the importance of daily sunscreen usage and foundation partners. featured celebrity spokespeople including Diane Keaton, Eva Longoria, Lea Michele and Aimee Mullins.

MRA greatly enhanced its online presence from 2013 to 2014 through media opportunities, social media outreach and a series of self-branded infor- mational and educational videos. On Facebook and Twitter, MRA’s scientific voice is increasingly acknowledged and echoed in messaging communications by pharmaceutical companies, research institutions and foundations and often intersects with its corporate allies’ promotional efforts. When compared to Melanoma Awareness Month in May 2013, MRA realized a 50% increase in website hits in May 2014, a 162% increase in the number of times its content was retweeted and a near doubling of Twitter followers. Stand Up To Cancer (SU2C) In 2012, MRA partnered with SU2C to fund a Melanoma Dream Team led by Drs. Jeffrey Trent and Patricia LoRusso. This year, MRA announced its sec- ond Dream Team collaboration with SU2C. Along with the Cancer Research Institute (CRI), this three-year $10 million Immunology Translational Research Dream Team led by Drs. James Allison and Antoni Ribas focuses on the complex relationship between cancer and the immune system, with the goal of enhancing immune-based therapies for cancer patients. MRA’s funding will support an extension of the team’s research into a melanoma-specific examination of the immune mechanisms underlying patients’ response to novel immunotherapies.

24 25 Melanoma Awareness Month—May 2014 May offered an important opportunity for MRA and its partners to advance the mission of reducing suffering and death from skin cancer. MRA partnered with 17 corporate partners to generate funding and awareness through cause marketing and outreach programs. These programs highlighted the dangers of melanoma, educated the public about how to reduce risk, and provided ways for people to take action. This past May, MRA’s sun safety and preven- tion messaging made more than 300 million impressions around the world.

Outreach and Fundraising Campaigns: TSA, American Idol® Live! For the fourth consecutive year, Sports Authority launched an in-store dona- Conference Engagement tion and consumer awareness program to raise funds for MRA’s research pro- MRA leadership regularly engages in conferences around the world. In 2014, gram and to help educate customers on ways to reduce their risk of melanoma. MRA was well-represented on “Cancer Immunotherapy: The Silver Bullet Against Cancer?” a panel at the Milken Institute Global Conference, which MRA also partnered for a second year with the American Idol Live! Tour discussed developments and challenges in cancer immunotherapies. 2014. For every ticket purchased for the Tour, American Idol Live! donated $1 to MRA. The Tour hit 40 different cities across the U.S. throughout the summer. Dermatology Council Venues broadcast the aforementioned L’Oréal Paris PSAs at their shows to fur- The MRA Dermatology Council was established in 2014 to engage leaders in ther underscore the partnership with MRA and encourage audience members the field of dermatology to advise, assist and make recommendations to MRA to be sun safe. on matters related to prevention, diagnosis and early treatment of melanoma. Press Highlights By engaging further with these physicians in both academic and private prac- tice, MRA expects to identify new opportunities for research, education and MRA was ranked first out of the top 30 grant-giving disease foundations by Ge- intervention. MRA also anticipates reaching a wider segment of the population netic Engineering & Biotechnology News. The ranking was determined by the by working with dermatologists on the frontline of melanoma care. percentage of total revenues each foundation devoted to grants and awards.

MRA leadership was frequently sought out and featured in national news Looking Forward: Patient Engagement Program media outlets, including The Huffington Post, the Washington Post, CNN As MRA continues to accelerate progress and fulfill its mission of eliminat- and Fox News for expert commentary on melanoma research, detection and ing suffering and death due to melanoma, there is enhanced opportunity to prevention news. expand the organization’s impact in the community through patient engage-

Lifestyles magazine featured an in-depth profile of Co-founder and Board Chair ment activities. The goal of MRA’s new patient engagement program is to #1 Grant Giving Debra Black. leverage MRA’s deep scientific and clinical reach and position MRA as a Disease Foundation resource for newly diagnosed patients, individuals receiving treatment and MRA has been featured on the AOL homepage as the ‘Cause of the Day’ those seeking to participate in clinical research. MRA has already initiated every year in May since 2012. The feature drove more than 11,000 visitors to the first phase of these activities through the creation of two new educa- the MRA website in 2014, outperforming AOL’s module average. tional videos on the latest advances in immunotherapy in collaboration with Health Guru and the development of an immunotherapy patient forum with other cancer foundations.

26 Outreach & Communications 27 Donors and Supporters Supporters 1/1/2013 to 12/31/2013 & Financials *Multi-year donor

h $500,000 Akin Gump Strauss Hauer & Feld LLP* Hess Foundation, Inc.* The Jeffrey A. Altman Foundation* L’Oréal Paris* Debra and Leon Black* Nancy and Howard Marks* Bloomberg Philanthropies* The Stewart J. Rahr Foundation* Christie’s* The Ressler Family Foundation* Jeffrey Epstein VI Foundation Saban Family Foundation* Jami Gertz and Tony Ressler* Sokoloff Family Trust*

$250,000-$499,999 $100,000-$249,000 $50,000-$99,999 Bank of America* Aon* 19 Entertainment Bristol-Myers Squibb Company The Bell Family Foundation, Inc.* Anonymous The Carson Family Charitable Trust* Jill and Jay Bernstein* Sunny and Norman Brownstein* Credit Suisse* Katie and Todd Boehly* Ernst & Young* Ellen and Gary Davis Foundation* Brownstein, Hyatt, Farber & Schreck* Goldman Sachs & Co. GlaxoSmithKline* Celgene Judy and John Hannan Hidary Foundation* Claire’s Boutiques, Inc. IPREO Debtdomain Kirkland & Ellis LLP* Deloitte* Denise and Michael Kellen Bennett S. LeBow* Amanda and Jonathan Eilian* Julie and Edward Minskoff Paul, Weiss, Rifkind, Wharton The Ellis Family* Mintz, Levin, Cohn, Ferris, Glovsky & Garrison LLP* Emilia Fanjul and Brian Pfeifler* and Popeo, P.E.* PricewaterhouseCoopers* Larry Gagosian Thomas Murphy Mary Jo and Brian Rogers* Daisy Helman* Sandy and Paul Norman Sotheby’s* James O. Robbins Family Charitable O’Melveny & Myers LLP* Sports Authority Lead Annuity Trust* Vinson & Elkins LLP* Elizabeth and Oliver Stanton Nancy and Richard Rogers Vital Projects Fund, Inc. Foundation* Fran and Jeff Rowbottom US Trust, Bank of America, N.A.* SkinCeuticals* Wachtell, Lipton, Rosen & Katz* The Viola Fund*

28 29 $25,000-$49,999 $5,000-$24,999 Fitch Ratings Clare McKeon Leanne and Richard Tavoso Sara Ferchichi Donna and William Acquavella AdvaMedDx Fried, Frank, Harris, Shriver & Merck & Co., Inc. Christopher J. Torrente Deborah M. Festa Jacobson LLP Amgen, Inc. Agenus, Inc. Richard N. Merkin Daniel Toscano James D. Forbes GA Partners Foundation Apollo Management, LP Mark Albert Michael E. Michetti Mindy and Marc Utay Freeborn & Peters LLP GE Capital Debbie and Mark Attanasio Alcenta Stan Middleman Thomas Wagner Scot French George W. and Elizabeth W. Kelly Emily and Len Blavatnik American Securities Advisors LLC Christina P. Minnis Deborah and Jeffrey Weber Rondi and David Frieder Foundation, Inc. BMO Capital Markets Krista and Devon Archer MJX Asset Management, LLC Wells Fargo Bank Kara Gaffney Ross and Stephen Ross Gibson, Dunn & Crutcher LLP Cahill Gordon & Reindel LLP Babson Capital Management LLC National Pharmaceutical Council White & Case LLP James Galowski GoldenTree Asset Management, Chapstick Heather and Michael Baker LP Natixis Global Asset Management Karen and Gary Winnick William Gates Citi Bank of America Merrill Lynch Lee Grinberg Alexander Navab Barbara and David Zalaznick Peter Glaser Joyce and Barry Cohen Barclays Capital H. Lee Moffitt Cancer Center & Margo and James Nederlander Dev Gopalan Research Institute Daiichi Sankyo Melissa and Dror Bar-Ziv Patty Newburger and Brad Wechsler $1,000-$4,999 Benjamin Grinberg David L. Klein, Jr. Foundation Biotechnology Industry The Harper Family Foundation Nomura Securities Lawrence B. Alletto Mary and Meyer Grinberg Organization The Derfner Foundation Hazen Polsky Foundation Amie and Scott Nuttall Kevin Arnold Lucy and Lawrence Guffey BlackRock Eli Lilly and Company HCA Holdings Oak Hill Advisors, LP Kathryn Bach Renee Harbers and Chris Liddell Laura and Lloyd Blankfein Caryl and Israel Englander Ronnie F. Heyman Peter O’Neill Renee and Richard Barasch Kristy and Robert Harteveldt The Blue Oak Charitable Fund Paul J. Fribourg Highbridge Capital Management, Orchard First Source Asset Nicole and Ron Beit-Halachmy William M. Hartnett Katherine Boden Holland LLC Genentech, Inc. Management Bergdorf Goodman, Inc. Christy Hedges Michele and Fred Brettschneider HSBC Bank Gail and Carl Icahn Craig Packer Vadim Berman Caroline Hirsch and Andrew Fox The Daniel & Estrellita Brodsky ICRAVE, LLC Laurie Kefalidis Post Advisory Group, LLC Big Orange Foundation Molly Johnson Family Foundation William Janetschek Kohlberg Kravis Roberts & Co. Provectus Pharmaceuticals, Inc. Judy and Charles Black Mark Kahn Shuly and William Bron Jefferies LLC The Marie-Josée & Henry R. Kravis The Reiss Family Foundation BNP Paribas Jason Kanner Foundation Richard J. Byrne Sarah and Stewart Kagan Avis and Bruce Richards David Boden Kelly’s Dream Latham & Watkins LLP Cabana Life The Kapnick Foundation James Robinson Bristol-Myers Squibb Foundation, Inc., Bonnie and Bradford Klein Jo Carole and Ronald Lauder Gaston Caperton Jill and Harry Kargman Royal Bank of Canada The Mitchell Kline Mizuho Securities USA, Inc. William H. Carter George Klein Christopher Rulon-Miller Timothy Broadbent Adam Kurzer Morgan Stanley Thomas W. Cole Jonathan Kolatch Ron Sabatino Elizabeth and Christopher Butler Bret Leas Morgan, Lewis & Bockius LLP James Connolly Cheryl and Alvin Krongard The Lawrence and Carol Saper Bruce Car Karen and Richard LeFrak Paul Hastings Frank Courtney Kristen and Charles Krusen Foundation Trudy and Paul Cejas Lili Lynton and Michael Ryan Pfizer, Inc. Crescent Capital Group Lan Lecour Bruce Schachne Patricia and Michael Chernick Earle I. Mack Lizanne and Barry Rosenstein Kara and James Cross Ashley Leeds and Christopher Jane and Nelson Schwab Clare Hare Darien Robert Marotta Daryl & Steven Roth Foundation Harland Carolyn and Marc Rowan Shearman & Sterling LLP John Cokinos Almedena and Pablo Legorreta MD Solarsciences Corp. Alison Sarofim and Stuart Parr Davis Polk & Wardwell Shenkman Capital Management, Inc. Bob Coors Medicomp Systems, Inc. Deutsche Bank The Loan Syndications & Trading Simpson Thacher & Bartlett LLP Skadden, Arps, Slate, Meagher & Flom CORE Media Group Association (LSTA) LLP Judith F. Minter Susan and Eric Smidt Eva and Brendan Dillon Looney Legacy Foundation Bradley W. Cuddeback Mott 50 LLC Susan Drossman Societe Generale Mary and David Solomon D.E.J. E., Inc. DBA Jimmy’s and Adam Sokoloff Howard M. Lorber Sony Music George Mueller The Thompson Family Foundation Jeanine Depasquale Salvatore and Kathryn and Philip Dunn Peter J. Lyon Gilliam and Robert Steel Hutham Olayan and Robert Raucci Eddie Trump Louis Salvatore Scott Edelman Priscilla and Connie Mack Alison and Leonard Stern Parasol UBS Charles Dubow Elizabeth Eielson Macquarie Group Stone Point Capital Foundation Inc. Tyler Patterson Mary Lynn and Bronson van Wyck Eaton Vance Erving and Joyce Wolf Foundation Sue and Tom Mandel Kelly and Jay Sugarman Louise Perkins Veritas Capital Management, LLC Entrogen, Inc. Susan and Peter Evensen Alison Mass and Sal Bommarito Sumitomo Mitsui Banking Corporation Sean H. Peters Leslie and Daniel Ziff Eric Javits, Inc. Andrea and George Ferris Christine and Joseph McGrath Hope and Glenn Taitz Prizeo

30 Supporters & Financials 31 Jonathan Ressler Clarke Adams Diane Bengston Thomas Buch Caryn Cohen Bilzin Carrie Diamond-Feldman and Jonathan Bilzin and H. Leigh Feldman Nancy Risman Veena and Sridhar Akenapally Brad Benson Barbara Bull Keith Cole Dennis Dillon Brian Robbins Sabina Albirt Harold Benson Susanne Bull Sherryl Coleman Clarissa Dimperio Jeffrey Rosen Marilyn R. Alper Sandy Benson John Burgess Tracy Coleman Kirsten Dineen Robert Rowe Joan and Lawrence Altman Cindy Bergmann Christopher Burns David Colla Michelle Dinenberg David T. Rubulotta Altus Group Karen and Brian Berkley Martha and Thomas Burns Gia Colunga Gina Diorio William Rutkoske Amica Companies Foundation Eric Berkowitz Jennifer and Norm Burstein Wynne and Philippe Comer Mark D. Director Pamela and Arthur Sanders Franklin Amoo Frederic Bernhard Michael J. Burton Jerome Connolly Donna Dolan Haley and Matthew Satnick Josh Amoss Jill Bettenhausen Susan and Alan Bushell John Connor Douglas Dolfie Wendy and Michael Selig Jill C. Anderson Vitoria and John Betz Amanda Buttenbusch Carolyn and Grafflin Cook Marcia and Frederick Donini Kevin Sherlock Ildiko Antal Whitney Beutel David Cadigan John Scott Cooke Kevin Dowd Doug G. Smith Michael Antonovich Chetan Bhandari Matthew Campobasso George Corey Donald G. Drapkin Manish Somaiya Paul Arbo Tina Bird Brian Candee Edward Corletzi Kim and Nick Drazic Ann and John Sorice Brian Archer Sanji Bizzarro Robert P. Candee Deb Cornejo Suzy Dritz Adam Soufleris Michael Arougheti Ryan Blackney W. Jane and Simon Canning Cosmopolitan Club Cecilia Ducharme Southmont JR.-SR. High School Matthew Assiff Sara Blakemore Rita Canova of Santa Barbara, Inc. John Dunn Debora and James Staley Associated Jewish Charities Alex Blau Emily Carey Elizabeth and Robert Craven Linda J. Durand Harriet and Ernest Steigman of Baltimore Roslyn and Allan Blau Diana M. Carnemolla Jay Creekmore Robin Dusek Meredith and Richard Steigman Caroline J. Atherton Jeffrey B. Bloom Alexandra Carney Marjorie C. Crichton Joshua Easterly Sun Protective Designer Clothing Rachel Atterberry Traci Otey Blunt Anne Carnicelli Sondra Cristal Richard Ebinger Pamela Sztybel and Elliott Stein Anthony Aufiero Dorothea Bobinski Janice Carroll Matthew Cudrin J Edwards Stephanie Teicher Sharyar Aziz John Boden Richard Carty Robin and Richard Cudrin Eileen Elias Fern and Leonard Tessler Cristina C. Bacon Rick Boden Joyce Caruthers Cunningham Supply, Inc. Karen Elizaga and Jay Ptashek W. Cade Thompson H. Gordon Baier Michael Bohigian John Cashman John Cushing Melissa and Douglas Ellin Adele Thurnher Helen Baker Sara Bolduc Joanne Chamberlain Cybergrants, Inc. Margot and Brian Erlich Evelyn and Jon Tomasson Susan and Jon Ballis Wendy Bollinger Gerald Chaney Sharon Dale Dawn Eslinger Tracy and Christopher Turner Betsy Barclay James Bonetti Mary Jane Chapline John D’Ambrosio Winfield Essex Thomas Uger Grant C. Barmby Michelle Booden Michelle Chapman Bonnie L. Damron Dan Esters Kevin Ulrich Jessica Barr Paul Borowski Barbara and Robert Charamut Brian Daniels Sarah and Preston Everdell Vineyard Vines, LLC Juliet Barr Jessica Botke Randy Chase Alice and Sabatino D’Ascanio Jennifer and Michael Ezell Trevor Watt David Barth Karen and Jon Boulanger John Chaski Kirk A. Davenport Erik Falk Abigail Wender Christine Bartus Seymour Boyers Mario Checca Corrinn Davis Frances and David Fall Jeremiah Whiddon Alan Bash Edgar Braunstein Andrew Cheng Robert Davis Jeff Farber Scott Willard Mark Basile Todd Bredbenner Amy Chenski Barbara and John Dawson Kevin Farley Rose and James Wolfe Eugene Bass Brelli Gloria Childress Teresa DeBenedictis Oakes Catherine Farrell Brian Yorke David Battle Christiopher Brescio Elizabeth Chorabik Valerie and Daniel Delaney Sandra J. Bauer Carol and Robert Brewer Eunu Chun Chris Fazio Brian Beal Armand and Lauren Della Monica Jim Feeley i $1,000 Joan and Ronald Brook Alison Clarke Marie DeMasi Jeanne Ferguson Dana Abatemarco Suzanne Beatty The Brooks Group Class Reunion Of 1956 Anne Dempsey Stephen and Megan Ferraro Catherine and Christopher Abbate Chris Becker and Associates, Inc. Kathleen Cleason David DeSantis Marcia Fettig Kathryn A. Abbott Loren Becker Susan and Mark Broude Catherine Clements Victor Dhooge Fidelity Charitable Gift Fund Frank Adamo Shirley and Denis Bellm Tom Brown Kenneth Coffey Gary Diamond

32 Supporters & Financials 33 Marilyn and Larry Fields Camille and Michael Gillespie Rick Harris Pyper Imperial Ethan Klemperer Gretchen Letson-Rask and Peter Rask Mary and John Filipkowski Diane and Ronnie Gilomen Dion Harrison Internet Society Fern and Arnold Klepner Richard Levenson Alberta E. Findeisen P. and Jerome Ginsburg Mary Hart Brian Iorio John Kline Greg Levi Paul Finger Michael Giordano Harvard Community Gifts Ira S and Anna Galkin Charitable Trust Kyle and Martin Klostermann Michelle Levy Maryann Finley Krista M. Giovacco John F. Hasler Cindy and Ike Isenhour Mishell B. Kneeland Shery Levy First Aid Beauty, LTD Suzanne Glad Cindy Hauer Joseph Jabes Jacob Koering Edward Lewis First Mid-Illinois Bank & Trust Laura Glennon Kristen Haunss Winifred Jackson Jennifer M Koller Maya Lin and Daniel Wolf D Geoffrey Fitton Erika Goedrich Brian Hayes Sandra Janiga Nancy and Joshua Korff Alana Linsenbigler Ethelyn and Edwin Flick Andrew L. Goldstein Erin Healy Zachary Jarvis Jean and Scott Korte Kevin Lockhart Joe Fogel Mitchell Goldstein Andrew Heller Katherine Jason Chris Kovel Brigette Loden Elyse Ford Ronnie Goldstein Neil Heller JBS international, Inc. Matthew J. Kramer Ronica Logani Karen P. Forman Michelle A. Golliday Tonita Helton Sarkis Jebejian Summer Kramer Brenda Lopez and Margaret Skubel Karen Fox Debra Gonzalez Pamela and Jonathan Henes Mark Jenkins Gail and Richard Krause Sarah Lowe Stephen Fraidin Virginia and Robert Good Betty Rae Henno Alison Jenks Ann Krieger Chiuwa E. Luk Cathy Franczyk Carrie Goodman Edward J. Hensler Candace and Jeffrey Johnson Patrick Kris April Luka Leslie Frausto Sam Goodyear Victoria Herbert Andy Jonusaitis David Kroner Kim Lundy Michael D. Freeborn Faith and Richard Gordon Don Hershberger Judith Ripka Creations, Inc. Donna Kronson Bina Luther Sara Freeland Marlene Gorke Christopher J. Herzog Christina Junior Ron Kubick Van Ly Holly Freeman William R. Goshorn Stephen E. Hessler Joyce and Lawrence Kabat Vinay Kumar Matthew Lynch Gail and Mark Frey Paula Granam Kara Heydecker Jarrod Kaplan Kristen Kuroski Lynne C. MacArthur Pamela and Kevin Frey Thomas Gravina Sean Hickey Lori Kaplan Thomas Kuroski Joseph P. Machuta Jan and Dan Froehlig Greater Twin Cities United Way Jack Hidary Rachel Kaplan and Howard Marlene B. Landon Kris Maciorowski Daniel Frommer Alan Green Lori and Michael Hiller Hershenhorn Heather Lang Deirdre Magarelli Matthew Fuller Robert Green Susan Hirschman Robert Kaplan Joseph A. Lang Matthew Magnuson Robert Fullerton Beatriz Greenberg Abigail Hoehne Joyce and Jerome Katz Steven Lang Michael Mahlstedt Robert Funk Nicole L. Greenblatt C. Holland Seth Katzenstein Bill Langford Arlene E. Maidman Anthony H. Gair Jeffrey Greenip Jacqueline Hollingsworth Marcia Kaufman Shirley LaPorte Nancy and Steven Manket Mary Lou and Donald Gallagher Brenton Greer LaVonne and Richard Holmes Jeanne Kaump Lee and Daryoush Larizadeh William Manning Elliot Ganz Ashley S. Gregory Darrick Hooker Wynne Keefer Judith Larson Punit Marathe Zenin Ganzon Barbara Grenzinski-Winalski and Patrick Horbac Marc Keislstein Laura Lausier Christopher Marcus Corey Geer Stephen Winalski Virginia M. Horn Billie Keitelman Christopher Lawler James Marshall Amy Gensler Marc D. Grossman Sally and Michael Horner Robert Keller Edgar Lawrence Gene Martin Teresa Gentile Cynthia and Thomas Gutzler Rosa and Daniel Horwath Sean Kelley Michael Lawton Patricia Martin Thomas George Linda and Joel Hahn Jill Howard Jeff Kelly Edward Lear Gregory Mason Nellie and James Gerlach Vicki and Grant Haley John Howard and Howard June Alan Kennedy Gowoon Lee Mary and R. D. Mason Brad Gerratt Sadia Halim Thomas M. Howard John Kilgallon Mary K. Lee Peter Mason Barbara D. Gholz Lucy Halperin and Jerold Zaro Kecia Howson Carolyn Kilkenney and Ryan Kilkenny Jeffrey Leen Ronni Massok Bessie T. Giannopulos Susan and Mark Hamlin Gary and Michele Hughes Dawn and Tim Killenberg Albert Lefkovits Linda M. Mastrone William Gianopoulos John Hammerle Amanda Hume Kim Kimberlin Lauren C. Leiman Omer Masud Kevin Gibbs Robert Hammond Earl Hunt Andrew Kirby David Lerner Luanne Matarangas Robert Giblichman Bernice and Dwight Harrelson James Hussney John Kitson Samuel Less Jeff Mattson Lisa Giesler Matthew Harrington Yongjin Im Stacy Klein and Les Olin Letarte Retail Greenwich LLC Ann W. May

34 Supporters & Financials 35 Scott McCallister Bridget Murphy Diane K. Palumbo Jane and Richard Raczek Verona Sandberg Aleesha Smith Maureen W. McCarthy Donna Murphy Alexander Pankov Kirk A. Radke Geri and Neal Sanderson Barry Smith Kimberly McConnell Kevin Murray Jeffrey Panzo Howard R. Ragin Paul Sandoli Bram Smith McCoy Family Trust My Tribute Gift Christian Paragot-Rieutort Robert T. Rahr Wendy and Edward Sassower Carol Smith and Christopher Walston Jo Ann McCoy John Myer Gregory Passaretti Frieda Ramaswamy Matthew Savino Charles Smith Sean McDermott Linda K. Myers Amanda Pastre Monika and Christine Rapp Joanna Scales Mitali Sohoni Debra McDonald Lisa Myers Eleanor Pearce Dombrowski Carl Scarpa Mary Soldat Al McGhee Shirley Myers Margaret Pedone Lisa Rapuano Elaine and Howard Schain Linda Sommers Deirdre McGuinness William Myers Pepsico Foundation Susan and Steven Ratner Sue and Kenneth Schechter Juliet Son Lori McKay Donna Mylenek The Perelson Family Trusts Laura and Michael Redmond Scott Schewe William B. Sorabella Nina McNealey Lauren Nadeau April and Jim Perez Jason Ridloff Beth Schlansky David Sorkin Bob McWilliams Christian O. Nagler Jaime Perez Elizabeth W. Ring Jenny Schmidt Gregory Sparer Jo-Anne and Jacques Meilleur- Cortney Nathanson Darlene Pergola Lynn and Steven Ritchie Phillip Schnell Laura and Stephen Spencer Lamoureux Carol Nebel Michelle and David Pestillo Steven Ritchie Anne and Ray Schrock George P. Stamas Andres Mena Michael Nechamkin David Peters James Roahen Karen Schroeder Nancy Stanley David P. Mendez Linda and Emil Nehrt Janet Petkin William Robbins Marcie and Douglas Schubert Allison J. Steigman Jackson Merchant Chris Neikirk John Petrozzi Carol Roberts and Mary Hom Mimi Schwartz Spencer Stenmark Merriam Sunshine Fund Carol and John Nelson Robert Pezzano Margaret Roberts Roberta Schwartz Susan Sterk Kenneth Mersel Cheryl Nelson Alan Phillips Larry Robertson Patricia Scott Sean Stevens Megan Messina Ronald W. Nelson Janice Phipps Nancy Robertson Ezra Segal Glenn Stewart Andrew Messinger Sally Nelson Mark Pibl Roger Robichaud Karen and Steven Seltzer James Stone Marcia Meth Tom Newberry Barbara Pieper Ashley Robinson Betty Serafin Robert Stopher Daniel Meyer Lila M. Newman Laura Pieper and Adam Cullin Helene and Jonathan Rod Randy Shacka Kathryn Storm Jane and Charles Meyer Maureen Newman Michael T. Pierce Bruce Rokjer John Shapiro Sara Subhani Kirstin and Carl Meyer Pamela and George Nixon Susan and Peter Pineault Robyn Roof T.J. Sheahan Phil Sutcliffe Donna Michael Leslie Nobile Francisco Pinto-Leite Lesley and Bradford Rope Jamie Shearer Jenni Swan Matthew Michelini Peter Nolan The Plainville Wind Ensemble B. J. Rosen Jill R. Shellow Maureen E. Sweeney Mike Middleman Matt Nord Kevin Pluff Paul Rosen Natalie L. Sherling John Sweeting Amy Miller Patti Nordon Justin Polselli Mary-Claire Ross Carolyn Shields Debra and Paul Taaffe Catherine Miller Morgan Nuckolls Minna and Rob Pomeroy Dean Rostovsky Cindy Shoemaker Ed Tam James F Miller Kathryn Oktavec Katherine Pond Stacey Roth Steven R. Shoemate Ivana Tarsia Tina L. Miller Arthur Oles Debra and Ronald Pook Susan Roth Paul Sigfusson Carson L. Taylor Lillian Millette Stephanie Oratz Basta and Paul Elizabeth Pook Even Rothenberg Pamela S. Silberman Christopher Taylor Braxton Mitchell Basta Alex Popov Griffin Rotman Greg Silva Janet and Richard Taylor Christina Mohs Karen Orfitelli Christopher Porter Ben B. Rubinowitz Linda Silva Robin and David Teh Patricia Monohan Debora Oriolo Karen and Lane Powell Joseph Ryan Chad Silver Meghan Tepas Sandra Lee and Cromwell Michele S. Orndorff Bart Powers Mike Ryan Karen and Dennis Simmons Ernita Thomas Montgomery Tom Otto Janet Pozmantier Wendy Sacks Beverly B. Simpson Kathryn Thomas Anna Morris Kimberly Owens Wise and John Jerianne Pugh Alex Sade Margot and C. Simpson Mark Thovson Diana and Peter Morse Wise Claire and Joseph Purcell Peter Saghir Mike Simpson Deborah W. Tiedrich Michael Movsovich Floyd G. Page Eman Quotah Peter Sakon Wendy and Todd Sinett DonnaLee and George Tignor James Moyne Randal Palach Frederick Raccosta Terry Sanabria Anthony Smeraglinolo John Timperio Cheryl and Ronald Mueller Catherine and Peter Palermo

36 Supporters & Financials 37 Robert Tintner Nick Whitney Linda Tishler Michael Wiggins Board of Directors Jeffrey Titus Kenneth Wiley Michael Tomasek Kirsten Wilkins Linda Torrey Jajuanna Williams Christine C. Totman Richard Williams Debra Black (Chair) Jeffrey Rowbottom Christina and Peter Toto Whit Williams Co-Founder – MRA; Phaidon Press Managing Director – Kohlberg Kravis Roberts & Michael Townsell Garry Wills Co. Sara Traberman Joseph Wilson Leon Black Edward Trageser Ray Winborne Co-Founder – MRA; Chairman, Chief Executive Elliott Sigal, M.D., Ph.D. Officer and Director – Apollo Management LP Former Executive VP and Chief Scientific Officer – Jeremy Traska Lenore Windsor Bristol-Myers Squibb Valorie Winkelman Travelers Maria Bell John Trentos Nancy Winkelstein and Christopher TV Writer and Producer Greg Simon Kiran Trivedi Plaut Chief Executive Officer – Poliwogg Joe and Dale Trott Joseph J. Winowiecki Ellen Davis Founder and Chair – JCC Greenwich; Catherine Twitmyer Trevor Winstead Jonathan W. Simons, M.D. President – UJA Greenwich President and Chief Executive Officer, David H. Kathy and Joseph Valentine Robert Wise Koch Chair – Prostate Cancer Foundation Beverly and Henry Wlodkowski Nipa Vatsaraj Amanda Eilian Brian Wolfe Robert Von Ancken Co-Founder and President – Videolicious Jonathan Sokoloff Daniel Vose Ira Wolfe (The Talk Market Inc.) Managing Partner – Leonard Green & Partners, LP Randy Wadle Kip Wolfe Jason Federici Liz Stanton Doug Wagner Frances and Raymond Wolski Art Director, Graphic Designer and Photographer Christina Wong President – Oliver and Elizabeth Stanton Kathleen Wagner Foundation Scott Woodworth Leon Wagner Jami Gertz Roberta Wald Patrick Woytek TV and Film Actress Suzanne Topalian, M.D. Heather Walters Michael Wright Professor of Surgery and Oncology; Director, Susan Hess Melanoma Program, Sidney Kimmel Amaris Wang Kathy Wuebbels Debbie and Brian Wulfson Vice Chairman – Whitney Museum Comprehensive Cancer Center – Johns Hopkins Lisa W. Wardell University Caesar Wyszomirski Jason Wasdin Michael Klowden Joe Yocom and Henry Woodside Heather Webb Chief Executive Officer – Milken Institute Staff (non-Director): Joseph Webb You Beauty Marvin Weinbaum Kenneth Young Connie Mack III Wendy Selig Senior Policy Advisor – Liberty Partners Group LLC Geralyn and Gerald Weis Maggie Young President and Chief Executive Officer – Melanoma Kristen Zachariev Research Alliance Cynthia Weisbard Nancy Marks Wendy Weisbard Kimberly Zahour Chairman – Ralph Rucci Eric Weiss Craig Zaph Officers (non-Director): Jill Weiss Taurie Zeitzer and Goran Mihajlovic Cindy McCain Officers (non-Director) Humanitarian and Businesswoman Patrick Wellspeak Gene Zelek Margaret Anderson (Secretary) Jim Zilisch Executive Director – FasterCures Margaret Welsh and David Johnsen Michael Milken Lynn Wenzel Margaret and John Zucker Chairman – Milken Institute Tony Zumbo Kamyab Hashemi-Nejad (Treasurer) Medina White Director of Finance – Milken Institute Thomas Whitley Richard Ressler Founder and President – Orchard Capital Corporation; Co-Founder – CIM Group

38 Supporters & Financials 39 Committees Richard Gaynor, M.D. Grant Review Committee (2014) Charles Drake, M.D., Ph.D. Thomas Hornyak, M.D., Ph.D. Antoni Ribas M.D., Ph.D. Vice President, Oncology, Product Associate Professor, Oncology, Chief, Dermatology, VA Maryland Associate Professor, Department of Development and Medical Affairs – Eli MRA’s Grant Review Committee, Immunology and Urology; Director Health Care System; Associate Medicine – University of California, Los Scientific Advisory Panel (2014) Lilly and Company composed of leading experts in – Multidisciplinary Prostate Cancer Professor of Dermatology and Angeles melanoma and cancer research, is Clinic, Johns Hopkins Sidney Kimmel Biochemistry and Molecular Biology responsible for vetting all research Comprehensive Cancer Center – University of Maryland School of The MRA Scientific Advisory Michael Giordano, M.D. Medicine Stan Riddell, M.D. Panel advises, assists, and makes proposals we submit. Review is based Senior Vice President, Oncology and Member, Department of Immunology recommendations to the MRA on MRA’s key criteria: innovation, Immunosciences Development – Glenn Dranoff, M.D. – Fred Hutchinson Cancer Research leadership team on scientific matters scientific merit, and potential for rapid Bristol-Myers Squibb Director, Human Gene Transfer Roger Lo, M.D., Ph.D. Center and policies, including research needs progression to clinical testing. MRA’s Laboratory Core – Dana-Farber Director, Melanoma Clinic in and opportunities that may be targeted conflict-of-interest guidelines ensure Cancer Institute Dermatology; Assistant Professor, for funding and scientific symposia. a fair and unbiased progress. Final Jeffrey Legos, Ph.D. funding decisions are ratified by the Department of Medicine, Dermatology; Caroline Robert, M.D., Ph.D. Medicines Development Leader – MRA Board of Directors. Assistant Professor, Department of Professor of Dermatology, Head of the David Fisher, M.D., Ph.D. Molecular and Medical Pharmacology Suzanne Topalian, M.D. (Chair) GlaxoSmithKline Dermatology Unit – Institute Gustave Chief, Dermatology Service; Director, – University of California, Los Angeles, Roussy Professor of Surgery and Oncology; David Solit, M.D. (Chair) Melanoma Program, Massachusetts School of Medicine Director, Melanoma Program, Sidney Neal Rosen, M.D., Ph.D. General Hospital Cancer Center; Kimmel Comprehensive Cancer Center Associate Attending Physician, Enid A. Haupt Chair in Medical Genitourinary Oncology Service; Director, Cutaneous Biology Research Lynn Schuchter, M.D. – Johns Hopkins University Michal Lotem, M.D. Oncology – Memorial Sloan Kettering Associate Member, Human Oncology Center – Massachusetts General C. Willard Robinson Professor of Cancer Center and Pathogenesis Program – Memorial Hospital Senior Physician, Sharett Institute Hematology-Oncology; Attending of Oncology – Hadassah Hebrew James Allison, Ph.D. Sloan Kettering Cancer Center Physician, Hospital of the University University Hospital of Pennsylvania; Program Leader, Chairman, Department of Immunology; Steven Rosenberg, M.D. Thomas Gajewski, M.D., Ph.D. Melanoma Program, Abramson Director, Immunotherapy Platform; Chief, Surgery Branch – National Kim Margolin, M.D. (Co-chair) Associate Professor, Departments Cancer Center of the University Deputy Director, David H. Koch Center Cancer Institute, National Institutes of of Pathology and Medicine; Director, Richard Marais, Ph.D. of Pennsylvania; Division Chief, for Applied Research of Genitourinary Physician, Department of Medicine Health Immunology and Cancer Program – Director – Paterson Institute for Cancer Hematology-Oncology – University of Cancers – University of Texas MD – University of Washington/Seattle University of Chicago Comprehensive Research Pennsylvania Anderson Cancer Center Cancer Center Cancer Center Mace Rothenberg, M.D. Grant McArthur, M.B.B.S., Ph.D., Jonathan Simons, M.D. Christopher Austin, M.D. Senior Vice President and Chief Marcus Bosenberg, M.D., Ph.D. Medical Officer – Pfizer Oncology Levi Garraway, M.D., Ph.D. F.R.A.C.P. Chief Executive Officer and President, Director – National Center for Associate Professor of Dermatology Associate Professor of Medicine Professor; Co-Chair, Melanoma David H. Koch Chair – Prostate Cancer Advancing Translational Sciences, and Pathology – Yale School of – Dana-Farber Cancer Institute; and Skin Service; Head, Molecular Foundation National Institutes of Health Medicine Joshua Sharfstein, M.D. Associate Member – Broad Institute Oncology Laboratory; Head, Secretary of Health and Mental Translational Research Laboratory – Peter MacCallum Cancer Centre Alan Spatz, M.D. Boris Bastian, M.D. Hygiene – State of Maryland Steven Burakoff, M.D. Jeffrey Gershenwald, M.D. Professor – Jewish General Hospital/ Clinical Professor, Department Professor of Medicine, Hematology Professor, Department of Surgical Lady Davis Institute for Medical Dermatology – University of California, and Medical Oncology; Professor, Ellen Sigal, Ph.D. Oncology, Division of Surgery – Martin McMahon, Ph.D. Research San Francisco Oncological Sciences – Mount Sinai Chairperson and Founder – Friends of School of Medicine University of Texas MD Anderson Professor-In-Residence – University of Cancer Research Cancer Center California, San Francisco Suzanne Topalian, M.D. Paul Billings, M.D., Ph.D. Paul Chapman, M.D. Professor of Surgery and Oncology; Chief Medical Officer – Omicia Allan C. Halpern, M.D. Glenn Merlino, Ph.D. Steven Stein, M.D. Attending Physician, Melanoma/ Director, Melanoma Program, Sidney Senior Vice President, US Clinical Sarcoma Service – Memorial Sloan Chief, Dermatology Service – Memorial Chief, Laboratory of Cancer Biology Kimmel Comprehensive Cancer Center Sloan Kettering Cancer Center and Genetics – National Cancer – Johns Hopkins University Gideon Bollag, Ph.D. Development and Medical Affairs – Kettering Cancer Center Novartis Oncology Institute, National Institutes of Health Chief Executive Officer – Plexxikon Tanja de Gruijl, Ph.D. Meenhard Herlyn, D.V.M., D.Sc. Michael Weber, Ph.D. Professor and Program Leader, Drew Pardoll, M.D., Ph.D. Lynda Chin, M.D. Associate Professor – VU University Professor of Microbiology, Immunology Molecular and Cellular Oncogenesis Co-Director, Cancer Immunology and Professor; Chair, Department of Medical Center and Cancer Biology, Weaver Professor Program – The Wistar Institute Hematopoiesis Program; Professor of Genomic Medicine; Scientific Director, of Oncology – University of Virginia Oncology, Medicine, Pathology, and Institute for Applied Cancer Science Molecular Biology and Genetics – John – University of Texas MD Anderson Hopkins University School of Medicine Cancer Center

40 41 Medical Advisory Committee Roger Lo, M.D., Ph.D. Suzanne Topalian, M.D. (2014) Director, Melanoma Clinic in Professor of Surgery and Oncology; Thanks to the generous financial support of MRA’s Dermatology; Assistant Professor, Director, Melanoma Program, Sidney Statement of founders for administrative and fundraising expenses, Department of Medicine, Dermatology; Kimmel Comprehensive Cancer Center 100 percent of donations to MRA directly support mel- The MRA Medical Advisory Panel anoma research. The independently audited financial advises the MRA leadership team on Assistant Professor, Department of – Johns Hopkins University Molecular and Medical Pharmacology Financial Position statements of the Melanoma Research Alliance Foun- medical matters and policies including dation form the basis of the following information. medical consultations, clinical research – University of California, Los Angeles, Jedd Wolchok, M.D., Ph.D. needs and opportunities, clinical School of Medicine December 31, 2013 regulatory and policy initiatives, and Associate Attending – Memorial Sloan With Summarized Totals at December 31, 2012 public education about melanoma. Kettering Cancer Center Patricia LoRusso, D.O. Professor of Medicine; Associate Paul Chapman, M.D. (Chair) Director of Innovative Medicine – Yale MRA Staff 2013 Attending Physician, Melanoma/ Cancer Center Unrestricted Temporarily Total Total 2012 Sarcoma Service – Memorial Sloan Wendy K.D. Selig Assets Kettering Cancer Center Restricted Kim Margolin, M.D. President and Chief Executive Officer Physician, Department of Medicine David Fisher, M.D. – University of Washington/Seattle Cash $12,994,760 $1,320,099 $14,314,859 $10,961,694 Louise M. Perkins, Ph.D. Chief, Dermatology Service; Director, Cancer Center Contributions Receivable (Net) - 21,158,458 21,158,458 19,806,654 Chief Science Officer Melanoma Program, Massachusetts Prepaid Expenses and Other Assets 50,739 - 50,739 81,832 General Hospital Cancer Center; David Polsky, M.D., Ph.D. Prepaid and Equipment (Net) 41,846 - 41,846 27,278 Director, Cutaneous Biology Research Laura M. Brockway-Lunardi, Ph.D. Center – Massachusetts General Associate Professor of Dermatology Hospital and Pathology; Director, Pigmented Scientific Program Director Lesion Section – New York University Total Assets $13,087,345 $22,478,557 $35,565,902 $30,877,458 Langone Medical Center, Joan and Thomas Gajewski, M.D., Ph.D. Joel Smilow Research Center Lauren C. Leiman Professor, Departments of Pathology Director of Marketing and and Medicine – University of Chicago Development Antoni Ribas, M.D., Ph.D. Liabilities and Net Assets Associate Professor, Department of Jeffrey Gershenwald, M.D. Medicine – University of California, Los Alexandra Carney Professor, Department of Surgical Angeles Scientific Program Manager Liabilities Oncology, Division of Surgery – University of Texas MD Anderson Lynn Schuchter, M.D. Jennifer Engel Cancer Center Accounts Payable and Accrued Liabilities $218,230 - $218,230 $169,506 C. Willard Robinson Professor of Development Manager, Foundations Deferred Revenue 120,000 - 120,000 50,000 Hematology-Oncology; Attending and Campaigns Due to Affiliate 1,684 - 1,684 321,412 F. Stephen Hodi, M.D. Physician, Hospital of the University Associate Professor, Department of of Pennsylvania; Program Leader, Melanoma Program, Abramson Randy E. Marsh Medicine – Harvard Medical School; Total Liabilities 339,914 - 339,914 540,918 Director, Melanoma Center – Dana- Cancer Center of the University Executive and Operations Manager Farber Cancer Institute of Pennsylvania; Division Chief, Hematology-Oncology – University of Pennsylvania Henry Woodside Sancy Leachman, M.D., Ph.D. Development Manager, CRM and Donor Communications Net Assets Professor and Chair, Department of Susan Swetter, M.D. Dermatology; Director, Melanoma Professor of Dermatology; Director, Research Program, Knight Cancer Unrestricted 12,747,431 - 12,747,431 9,392,603 Institute – Oregon Health and Science Pigmented Lesion and Melanoma University Program – Stanford University Medical Temporarily Restricted - 22,478,557 22,478,557 20,943,937 Center and Cancer Institute Total Net Assets 12,747,431 22,478,557 35,225,988 30,336,540

Total Liabilities and Net Assets $13,087,345 $22,478,557 $35,565,902 $30,877,458

42 43 Statement of Activities

Year Ended December 31, 2013 With Summarized Totals for the Year Ended December 31, 2012

2013

Revenues, Public Support Unrestricted Temporarily Total Total 2012 and Other Income Restricted

Contributions $1,082,148 $7,030,450 $8,112,598 $3,664,602 Special Events (Net of Cost of Direct 3,989,318 3,294,000 7,283,318 4,666,666 Donor Benefits of $329,582) Sponsorships 161,250 - 161,250 207,500 Interst Income 38,065 - 38,065 29,985 In-Kind Contribution - - - 69,178 Other Income - - - 54,500 Net Assets Released from Purpose Restrictions 1,265,102 (1,265,102) - - Time Restrictions 7,524,727 (7,524,727) - -

Total Revenues, Public Support 14,060,610 1,534,621 15,595,231 8,692,431 and Other Income

Functional Expenses Program Services 9,650,631 - 9,650,631 8,476,752 Management and General 372,512 - 372,512 375,042 Fundraising 682,640 - 682,640 485,653

Total Functional Expenses 10,705,783 - 10,705,783 9,337,447

Change in Net Assets 3,354,827 1,534,621 4,889,448 (645,016) Net Assets - Beginning of Year 9,393,604 20,943,936 30,336,540 30,981,556

Net Assets - End of Year $12,747,431 $22,478,557 $35,225,988 $30,336,540

44 1101 New York Avenue, NW, Suite 620 Washington, DC 20005 curemelanoma.org [email protected]